<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069485</url>
  </required_header>
  <id_info>
    <org_study_id>5R01AI047086-03</org_study_id>
    <secondary_id>5R01AI047086-03</secondary_id>
    <nct_id>NCT00069485</nct_id>
  </id_info>
  <brief_title>Resistance to HIV Infection</brief_title>
  <official_title>Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The immune systems of some individuals may be capable of resisting HIV infection. These&#xD;
      individuals do not appear to be infected with HIV despite multiple sexual encounters with HIV&#xD;
      infected partners. This study will examine the immune systems of these individuals to&#xD;
      determine what factors are responsible for their ability to resist HIV infection.&#xD;
&#xD;
      Study hypothesis: Some long-term, multiply-exposed seronegative persons have relative&#xD;
      resistance to HIV infection maintained by T cell responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rare individuals appear naturally resistant to overt HIV-1 infection despite repeated sexual&#xD;
      exposures. These individuals, referred to as exposed seronegatives (ES), represent a unique&#xD;
      population in which to evaluate mechanisms by which HIV-1 replication is either controlled or&#xD;
      aborted. The purpose of the study is to analyze HIV-specific immune responses, both cellular&#xD;
      and humoral, that exist in seronegative individuals who have experienced multiple exposures&#xD;
      to HIV by sexual contact.&#xD;
&#xD;
      This study will follow participants for 2 years. Participants will have 25 study visits&#xD;
      during the study. Assessments will include HIV tests, viral load measurements, CD4 counts,&#xD;
      pregnancy tests, and physical exams.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 1995</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  HIV uninfected&#xD;
&#xD;
          -  Repeated exposures to HIV through unprotected sexual intercourse within the 2 years&#xD;
             prior to study entry&#xD;
&#xD;
          -  Live in the greater Seattle area&#xD;
&#xD;
          -  Plan to stay in the greater Seattle area for the 2 years after study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie McElrath, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center / University of Washington HIV Vaccine Trials Unit</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Louis</last_name>
      <phone>206-667-2300</phone>
      <email>klouis@fhcrc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>September 26, 2003</study_first_submitted>
  <study_first_submitted_qc>September 29, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2003</study_first_posted>
  <last_update_submitted>September 17, 2007</last_update_submitted>
  <last_update_submitted_qc>September 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2007</last_update_posted>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

